Text Size

Uterine Leiomyosarcoma Nomogram : Disclaimer

The prediction tools, also known as prognostic nomograms, located on the MSKCC Web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.

Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.

MSKCC makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSKCC does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect.

Use of the prediction tools does not create an express or implied physician-patient relationship. MSKCC does not endorse or claim validity for the prediction tools found on the MSKCC Web site. The activities and products of MSKCC and its developers and agents (collectively MSKCC) are not endorsed by our past, present, or future employers. MSKCC does not record specific prediction tool user information and does not contact users of the prediction tools.

You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that neither MSKCC nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.

I accept all of the above terms by clicking here or by any further use of this service.
I do not accept all of the above terms.

Uterine Leiomyosarcoma Nomogram: Overall Survival Probability

This tool predicts the chance of overall survival at five years following primary surgery for uterine leiomyosarcoma. It may be used by clinicians in assessing risk when deciding on follow-up strategies. Patients who use this tool should discuss the results with their physician to learn what these results mean for you.

CalculateClearEnter Your Information

(20 to 100 years)
Size of the primary uterine leiomyosarcoma tumor removed from the uterus, in centimeters.
cm
Loco-regional metastases are present if, at the time of surgery, the leiomyosarcoma was found in the structures near the uterus, including the bladder, nearby bowel, nearby lymph nodes, parametria, ovaries, or fallopian tubes.
Distant metastases are present if imaging studies either before or soon after surgery showed that the leiomyosarcoma had spread to distant areas such as the lung, liver, or bone.
This is expressed as the number of mitotic figures per 10 high-powered fields (hpf) seen under the microscope. If the pathology report gives a range (such as 8-20 mitoses/10 hpf) use the higher number (20 mitoses/10 hpf). The nomogram calculator will make a logarithmic transformation of the mitotic rate.
mitoses/10 hpf

Learn More About Your Results

Probability of overall survival

This tool predicts the chance of overall survival at five years following primary surgery for uterine leiomyosarcoma. It may be used by clinicians in assessing risk when deciding on follow-up strategies. This nomogram incorporates other individualized patient variables beyond FIGO stage to more accurately predict outcome. Patients who use this tool should discuss the results with their physician to learn what these results mean for you.

Supporting Publication

A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. Cancer. 2012 Feb 1;118(3):660-9.